Ligand PharmaceuticalsFRA:LGDN +1.57%76 Days Payable is 117.90 as of Mar. 2026, which is 1% above its 10-year median of 116.25. GuruFocus rates FRA:LGDN with a GF Score™ of 76/100 and a GF Value™ of €145.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 705 Biotechnology companies, Ligand Pharmaceuticals ranks better than 56.6% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LGDN vs DFTX, CGON, XENE: Days Payable Comparison
For the Biotechnology subindustry, Ligand Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ligand Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals (FRA:LGDN) has a Days Payable of 117.90 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ligand Pharmaceuticals and its competitors. This is near median its historical median of 116.25. Over the past decade, Ligand Pharmaceuticals' Days Payable has ranged from 35.77 to 223.32. According to the industry distribution chart, Ligand Pharmaceuticals ranks #306 out of 705 companies in the Biotechnology industry, placing it in the top 43.4%.
Is Ligand Pharmaceuticals' Days Payable too high?
Ligand Pharmaceuticals' current Days Payable of 117.90 is near median its 10-year median of 116.25. Over the past 10 years, this metric has ranged from a low of 35.77 to a high of 223.32. The Biotechnology industry median Days Payable is 113.36. Ligand Pharmaceuticals' value of 117.90 is 4% above this industry median. Based on the distribution chart, Ligand Pharmaceuticals ranks #306 out of 705 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ligand Pharmaceuticals has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Days Payable compare to DFTX and CGON?
According to the Biotechnology industry distribution chart, Ligand Pharmaceuticals ranks #306 out of 705 companies for Days Payable. This puts Ligand Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 113.36. Ligand Pharmaceuticals' value of 117.90 is 4% above this benchmark. Historically, Ligand Pharmaceuticals' own Days Payable has ranged from 35.77 to 223.32 over the past decade. While the company's 10-year median is 116.25 vs. the industry median of 113.36, Ligand Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ligand Pharmaceuticals's current Days Payable of 117.90 is 4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ligand Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ligand Pharmaceuticals's current Days Payable is 117.90, which is near median its own 10-year median of 116.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €145.02, compared to a current price of €258.00 — trading 77.9% above its estimated fair value. The current Days Payable is 117.90, which is near median its 10-year median of 116.25 and 4% above the Biotechnology industry median of 113.36. Ligand Pharmaceuticals' overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Days Payable is 117.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?
Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued.
The current stock price of €258.00 is trading 77.9% above its estimated GF Value™ of €145.02.
GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:LGDN:
Days Payable: 117.90 (near median its 10-year median of 116.25)
GF Value™: €145.02 vs. price of €258.00 (77.9% above fair value)
Industry Position: 4% above the Biotechnology median (#306 of 705)
No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
76GF Score
Get the complete analysis for FRA:LGDN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LGDN has been successfully added to your 
